Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

Apostolia Maria Tsimberidou, MD, PhD

doi:10.1093/oncolo/oyag249

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

2026-06-29

0

OA

AI

A

Apostolia Maria Tsimberidou, MD, PhD *

D

Darren Sigal, MD

A

Anna Varghese, MD

D

Daniel Vaena, MD

L

Li-Yuan Bai, MD, PhD

M

Ming-Huang Chen, MD, PhD

C

Chun-Nan Yeh, MD

C

Chia-Jui Yen, MD

M

Mehmet A Baysal, MD

A

Abhijit Chakraborty, PhD

I

Ingly Lee, MS

C

Chi-Sheng Shia, PhD

K

Konul Ristoski, MD

D

Dong Xu, PhD

DOI：10.1093/oncolo/oyag249

Original

Original request for help

Save

Abstract

En 中文

OBI-999 is an antibody-drug conjugate consisting of the Globo H–targeting antibody OBI-888 linked to the cytotoxic payload monomethyl auristatin E. In a dose-escalation study, the OBI-999 recommended phase 2 dose (RP2D) was 1.2 mg/kg every 3 weeks. This dose-expansion study evaluated the efficacy and safety of OBI-999 in patients with pancreatic cancer, colorectal cancer (CRC), or other tumor types (“basket cohort”) and tumoral Globo-H H-scores ≥100 (NCT04084366).

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

Abstract

Journal

Organization

Cited Papers

Citing Papers